RxDoctor Payments Data

Christopher Elliott, MD

Urology · Stanford, CANPI 1609063262

Payments from drug & device makers

$3,120in general payments, 2019–2025

Across 23 payments — averaging $135.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bluewind Medical$1K
  • C. R. Bard, Inc. & Subsidiaries$650
  • Stryker$430
  • Medtronic$285
  • Coloplast$211
  • AbbVie$92
  • plus $131 from 3 others

What the payments were for

  • Consulting fees$1,08035%
  • Travel & lodging$1,12736%
  • Food & beverage$91329%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bluewind Medical9$1,322
C. R. Bard, Inc. & Subsidiaries2$650
Stryker1$430
Medtronic(2 entities)2$285
Coloplast4$211
AbbVie2$92
Astellas Pharma US Inc1$70
Boston Scientific1$41
180 Medical, Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,120 in reported general payments places this provider in the 50th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$78,808
Medicare patients
366
Services billed
738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron304$319,047
GemtesaVibegron37$47,209
Oxybutynin Chloride ErOxybutynin Chloride280$7,293
Mirabegron ErMirabegron14$5,928
RenacidinCitric Ac/Gluconolact/Mag Carb31$5,607
Trospium Chloride ErTrospium Chloride11$2,906
Tolterodine Tartrate ErTolterodine Tartrate22$2,330
Potassium Citrate ErPotassium Citrate21$1,884
Trospium Chloride23$1,700
NitrofurantoinNitrofurantoin Macrocrystal27$943
Finasteride50$619
Estradiol16$552
Amitriptyline Hcl12$446
Tamsulosin Hcl51$390
Cephalexin15$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$70$319,047304 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,324 urology providers in California.

Other urology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →